Two main approaches are being pursued for DMD: (1) the restoration of dystrophin (or of dystrophin surrogate molecules) at the sarcolemma in order to improve the structural integrity of muscle fibers or (2) therapeutic attempts dealing with secondary consequences of dystrophin deficiency and the progressive dystrophic pathology. The gene discussed is DMD; the disease is hyperinsulinemic hypoglycemia, familial, 4.